Circulating monocytes of FH patients not on statins showed a pro-inflammatory phenotype and intracellular lipid accumulation, which was reversed upon treatment with PCSK9 antibodies.
Evolocumab CV outcomes study meets primary and key secondary endpoints, showing reduced risk of CV events in those with ASCVD already on optimised statin therapy.
CSI Rome Kausik Ray was involved in a project which investigated in UK databases which proportion of the predicted population with FH has been identified and is labelled as such. Johanneke van den Berg and Corien Flint discuss the consequences of underdetection with him, and how this may be improved.
EAS 2016 Gene therapy targeted at LDLR and HMGCR decreased LDL-c level and slowed atherosclerosis in mice.
Daniel Rader (Philadelphia, PA, USA) looks forward to a future of personalised medicine in FH, which should benefit from specific biomarkers and novel medications, to better treat this common lipid disorder. But first, FH patients need to be better identified.
Evolocumab is the second PCSK9 inhibitor that is approved for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous or homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease.
Lipid MC 2015 Prof. Frederick Raal considers the challenges to adequately lower LDL-c levels in patients with HoFH, and how they may be overcome in the near future.
ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.
Lipid MC 2015 Dr. Kees Hovingh discusses recent insights into the actual prevalence of homozygous and heterozygous FH, how FH patients can best be identified, and how they should be managed.
ISA 2015 The European Atherosclerosis Society (EAS) Consensus Panel publishes a position paper today that makes the case for renewed efforts to detect and manage FH children so as to reduce the burden of death and disability associated with this common condition.
We are pleased to announce our first PACE Lipid Master Class: 'A case-based approach to advanced lipid management' to be held on May 22-23, 2015 in Amsterdam, prior to ISA2015. The meeting will be held in collaboration with MedPace 'FH-Clinician'.
Dr. Janneke Wittekoek (director LEEFH Foundation) explains how a unique collaborative effort, paid for by reimbursements from insurance companies, sets out to find all patients with familial hypercholesterolaemia in The Netherlands.